PETROS PHARM (PTPI) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 26, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PTPI SEC filings page.
This page shows PETROS PHARM INC (PTPI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Reported profit in FY2025 came alongside operating losses and cash outflow, while financing reshaped a much smaller balance sheet.
FY2025 net income was$1.9M , but operating income showed a$4.6M loss and operating cash flow was-$6.7M . That combination indicates the reported profit did not come from core operations and was not converted into cash.
The balance sheet moved from negative equity of
FY2025 financing cash flow was
Financial Health Signals
PETROS PHARM INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
PETROS PHARM INC passes 4 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, all 2 leverage/liquidity signals pass.
For every $1 of reported earnings, PETROS PHARM INC used $3.52 of operating cash (-$6.7M OCF vs $1.9M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.
Key Financial Metrics
Earnings & Revenue
PETROS PHARM INC reported a net loss of $956K in Q2 2026. This represents a decrease of 117.6% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q2 2026.
Not reported for Q2 2026.
Cash & Balance Sheet
PETROS PHARM INC held $3.5M in cash as of Q2 2026; no long-term debt figure is on record for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
PETROS PHARM INC's quarterly ROE was -136.3% in Q2 2026: one quarter's net income over shareholder equity, not annualized. This is down 258.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 80.6 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
None of these metrics is reported for Q2 2026.
PTPI Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | $725K | $1.6M-5.9% |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | $265K | $287K-29.7% |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | $461K | $1.3M+1.8% |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | $102K | $588K+51.2% |
| SG&A Expenses | $989K-45.1% | $1.0M-29.6% | N/A | $991K-17.3% | $1.8M+33.5% | $1.5M-3.0% | $578K | $1.2M-40.2% |
| Operating Income | -$989Kn/m | -$1.0Mn/m | N/A | -$991Kn/m | -$1.8Mn/m | -$1.5Mn/m | -$578K | -$1.2Mn/m |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | $79K | -$458Kn/m |
| Net Income | -$956K-117.6% | -$987Kn/m | N/A | -$923Kn/m | $5.4Mn/m | -$2.3Mn/m | -$9.3M | -$2.2Mn/m |
| EPS (Basic) | -$0.30 | -$0.03 | $0.39n/m | -$0.03 | -$1.20 | -$9.37 | -$1.16 | -$16.65 |
| EPS (Diluted) | -$0.30 | -$0.03 | $0.39n/m | -$0.03 | -$1.20 | -$9.37 | -$1.16 | -$16.65 |
| Diluted Shares (Avg) | 47M | 46M | N/A | 42M | 26M | 1M | N/A | 393,192 |
Not reported in any period shown, so not listed: Interest Expense, Income Tax.
PTPI Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $3.5M-52.1% | $4.4M-75.0% | $5.2M-51.4% | $6.1M-70.4% | $7.4M-70.6% | $17.6M-41.9% | $10.6M-68.5% | $20.7M-46.8% |
| Current Assets | $3.5M-52.1% | $4.4M-69.6% | $5.2M-29.2% | $6.1M-42.8% | $7.4M-47.1% | $14.5M-19.2% | $7.3M-64.2% | $10.7M-56.1% |
| Cash & Equivalents | $3.5M-52.4% | $4.4M-51.3% | $5.1M+198.9% | $6.1M+55.6% | $7.3M-2.4% | $8.9M-19.5% | $1.7M-87.1% | $3.9M-78.3% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | $1.3M-16.2% | $1.4M-43.8% |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | $416K-81.3% | $1.9M-34.5% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $2.8M-3.6% | $2.6M-90.4% | $2.3M-87.3% | $2.8M-84.3% | $2.9M-81.5% | $27.2M+38.6% | $18.1M-15.1% | $17.6M-44.8% |
| Current Liabilities | $2.8M-3.6% | $2.6M-90.3% | $2.3M-87.3% | $2.8M-78.0% | $2.9M-70.4% | $27.1M+141.8% | $18.0M+67.4% | $12.6M+55.4% |
| Non-Current Liabilities | $0n/m | $0-100.0% | $0-100.0% | $0-100.0% | $0-100.0% | $58K-99.3% | $75K-99.3% | $5.0M-78.9% |
| Total Equity | $701K-84.2% | $1.8Mn/m | $2.9Mn/m | $3.4M+8.1% | $4.4M-44.9% | -$9.6M-197.9% | -$7.5M-161.9% | $3.1M-55.1% |
| Retained Earnings | -$113.2Mn/m | -$112.3Mn/m | -$111.3Mn/m | -$111.0Mn/m | -$110.0Mn/m | -$115.5Mn/m | -$113.2Mn/m | -$103.9Mn/m |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
PTPI Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$864Kn/m | -$784Kn/m | -$934K-196.7% | -$1.1Mn/m | -$3.0Mn/m | -$1.7Mn/m | $965Kn/m | -$771Kn/m |
| Depreciation & Amortization | N/A | N/A | N/A | N/A | N/A | N/A | $656K-18.3% | $739K-10.6% |
| Stock-Based Compensation | N/A | $120K+50.3% | N/A | N/A | N/A | $80K-55.6% | N/A | $0-100.0% |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | $5K | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | $960K | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | -$5K | N/A |
| Financing Cash Flow | N/A | N/A | $0n/m | -$117Kn/m | -$428Kn/m | $8.7Mn/m | -$1.1Mn/m | -$2.8M-119.0% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
PTPI Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | 63.5% | 81.8%+6.2pp |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | -79.6% | -76.0% |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | -1278.4% | -140.9% |
| Return on Equity | -136.3%-258.5pp | -55.7% | N/A | -27.4%+43.9pp | 122.2%+130.4pp | N/A | N/A | -71.3%-5.6pp |
| Return on Assets | -27.0%-100.4pp | -22.5%-9.6pp | N/A | -15.0%-4.3pp | 73.5%+76.1pp | -12.8%-5.7pp | -87.2% | -10.7%+1.0pp |
| Current Ratio | 1.25-1.3x | 1.68+1.1x | 2.25+1.8x | 2.22+1.4x | 2.51+1.1x | 0.53-1.1x | 0.40-1.5x | 0.85-2.2x |
| Liabilities-to-Equity | 4.06+3.4x | 1.48 | 0.80 | 0.82-4.8x | 0.66-1.3x | N/A | N/A | 5.64+1.0x |
| Asset Turnover | N/A | N/A | N/A | N/A | N/A | N/A | 0.07 | 0.080.0x |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | 132.3% | N/A |
Not reported in any period shown, so not listed: Debt-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin, FCF Margin.
Where PETROS PHARM INC Ranks
Frequently Asked Questions
Is PETROS PHARM INC profitable?
Yes, PETROS PHARM INC (PTPI) reported a net income of $1.9M in fiscal year 2025.
What is PETROS PHARM INC's return on equity (ROE)?
PETROS PHARM INC (PTPI) has a return on equity of 66.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is PETROS PHARM INC's operating cash flow?
PETROS PHARM INC (PTPI) recorded an outflow of $6.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are PETROS PHARM INC's total assets?
PETROS PHARM INC (PTPI) had $5.2M in total assets as of fiscal year 2025, including both current and long-term assets.
What is PETROS PHARM INC's current ratio?
PETROS PHARM INC (PTPI) had a current ratio of 2.25 as of fiscal year 2025, which is generally considered healthy.
What is PETROS PHARM INC's liabilities-to-equity ratio?
PETROS PHARM INC (PTPI) had a liabilities-to-equity ratio of 0.80 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
What is PETROS PHARM INC's return on assets (ROA)?
PETROS PHARM INC (PTPI) had a return on assets of 37.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is PETROS PHARM INC's P/E ratio?
PETROS PHARM INC (PTPI) trades at 0.0x earnings, its market capitalization divided by $1.9M net income, FY2025. The market capitalization is $81K as of Oct 26, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is PETROS PHARM INC's price-to-sales ratio?
PETROS PHARM INC (PTPI) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $81K as of Oct 26, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does PETROS PHARM INC's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, PETROS PHARM INC (PTPI) held $5.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $6.7M over that year. Dividing the one by the other, the reported balance equals about 9 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is PETROS PHARM INC's Piotroski F-Score?
PETROS PHARM INC (PTPI) has a Piotroski F-Score of 4 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are PETROS PHARM INC's earnings high quality?
For every $1 of reported earnings, PETROS PHARM INC (PTPI) used $3.52 of operating cash (-$6.7M OCF vs $1.9M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.